III. Incretin-based Therapeutics for Type 2 Diabetes

Key Points

• This research explores the role of incretin-based drugs in managing type 2 diabetes, focusing on their benefits and implications.
• Review of incretin-based drug classes, including DPP-4 inhibitors and GLP-1 receptor agonists.
• Evaluation of their effects on insulin secretion and glycemic control.
• Analysis of cardiovascular and kidney protective benefits of these therapies.
• DPP-4 inhibitors and GLP-1 receptor agonists enhance insulin secretion while reducing the risk of hypoglycemia.
• GLP-1 receptor agonists also promote weight loss and offer cardiovascular and kidney protection.
• These therapies are critical for treating obesity-related type 2 diabetes in younger populations.